α1A-Subtype Adrenergic Agonist Therapy for Failing Right Ventricle

• Published in: American journal of physiology. Heart and circulatory physiology Vol. 313; no. 6; pp. ajpheart.00153.2017 - H1118
• Main Authors: Cowley, Patrick M, Wang, Guan-Ying, Joshi, Sunil K, Swigart, Philip M, Lovett, David H, Simpson, Paul C, Baker, Anthony J
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.12.2017
• Series: Heart Failure: Novel Therapeutic Pathways Emerging from Basic Science
• Subjects: alpha-1 adrenergic; right ventricle; therapy; myofilament; reactive oxygen species
• ISSN: 0363-6135; 1522-1539
• DOI: 10.1152/ajpheart.00153.2017

Failure of the right ventricle (RV) is a serious disease with a poor prognosis and limited treatment options. Signaling by α1-adrenergic receptors (α1-ARs), in particular the α1A-subtype, mediate cardioprotective effects in multiple heart failure models. Recent studies show that chronic treatment with the α1A-subtype agonist A61603 improves function and survival in a model of LV failure. The goal of this study was to determine if chronic A61603 treatment is beneficial in a RV failure model. We used tracheal instillation of the fibrogenic antibiotic bleomycin in mice to induce pulmonary fibrosis, pulmonary hypertension, and RV failure within 2 wk. Some mice were chronically treated with a low dose of A61603 (10ng/kg/day). In the bleomycin model of RV failure, chronic A61603 treatment was associated with improved RV fractional shortening, and greater in-vitro force development by RV muscle preparations. Cell injury markers were reduced with A61603 treatment (serum cardiac troponin-I, RV fibrosis, and expression of matrix metalloproteinase-2). RV oxidative stress was reduced (using the probes dihydroethidium and 4-hydroxynonenal). Consistent with lowered RV oxidative stress, A61603 was associated with an increased level of the cellular antioxidant superoxide dismutase 1 and a lower level of the pro-oxidant NAD(P)H oxidase isoform NOX4. In summary, in the bleomycin model of RV failure, chronic A61603 treatment reduced RV oxidative stress, RV myocyte necrosis and RV fibrosis, and increased both RV function and in-vitro force development. These findings suggest that in the context of pulmonary fibrosis, the α1A-subtype is a potential therapeutic target to treat the failing RV.